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[57] ABSTRACT 
A composition and method for treating hyperglycemia 
which utilize an extract of the Chinese herb Polygonum 
multifiorum. The herb is extracted with 0.lN NH4OH and 
centrifuged. The supernatant is applied to a Sephadex G-25 
column. Three fractions are collected. The fractions exhibit 
a high insulin potentiating activity in fat cell assays and are 
shown to lower blood glucose levels. 
7 Claims, No Drawings 
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COMPOSITION AND METHOD FOR 
TREATING HYPERGLYCEMIA UTILIZING 
AN EXTRACT OF POLYGONUM 
MULTIFLORUM 
2 
has established the following criteria for classifying these 
illnesses. 
TABLE 1 
DIAGNOSTIC CRITERIA OF THE NATIONAL DIABETES DATA GROUP 
Criteria for Diagnosis of Diabetes Mellitus and 
Impaired Glucose Tolerance 
Criteria for Diagnosis 
of Gestational 
Diabetes (All plasma glucose values in mg/dL) 
Normal Diabetes Mellitus 
Adult Child Adult Child 
FPG <115 <130 ?,140 ?,140 
OGTT <140 <140 ?,200 ?,200 
Impaired Glucose 
Tolerance 
Adult Child 
115-139 130-139 
140-199 140-199 
(100 gm OGTT) 
Venous Plasma 
Glucose 
Fasting ?, I 05 mg/dL 
lh ?, 190 mg/dL 
2h ?, 165 mg/dL 
3h ?, 145 mg/dL 
FPG = fasting plasma glucose; 
OGTT = oral glucose tolerance test (at least 2 values). 
From Harris M., et al for the National Diabetes Group: "Classification and diagnosis of diabetes mellitus 
and other categories of glucose intolerance." Diabetes 28:1049, 1979. Copyright 1979 by American 
Diabetes Association, Inc. 
BACKGROUND OF THE INVENTION 
This invention relates to the use of fractions of an extract 
of a Chinese herb in treating hyperglycemia. 
25 
The most well known of these disorders is diabetes 
mellitus. Diabetes mellitus is characterized by hyperglyce-
mia resulting from impaired insulin secretion and is asso-
ciated with a host of late complications including retinopa-
The monosaccharide carbohydrate glucose is present in 
the blood of animals. It is the body's primary source of 
energy for cell metabolism, and it comes principally from 
the digestion of other carbohydrates. Despite wide variations 
in carbohydrate intake, and consequent large fluctuations in 
the amount of glucose absorbed by the body, the concen-
tration of glucose in the blood, commonly referred to as the 
blood sugar level, is normally kept within narrow limits. In 
humans fasting blood glucose concentrations are considered 
normal if between 70 mg/di and 114 mg/di. 
30 thy, nephropathy, atherosclerotic coronary and peripheral 
arterial disease, and peripheral and autonomic neuropathies. 
There are two main types of diabetes mellitus. In Type I, or 
insulin dependent diabetes (also known as juvenile diabe-
tes), the insulin-secreting cells in the pancreas are destroyed 
35 and insulin production ceases almost completely. Type II, or 
non-insulin-dependent diabetes (adult-onset diabetes), is 
usually marked by gradual onset wherein insulin is pro-
duced, but not in sufficient quantity to fully metabolize 
blood glucose. Both types result in an abnormally high level 
of glucose in the blood, which, ifleft uncorrected, can cause 
40 coma and death. In the United States alone about 150 to 200 
persons per 100,000 have the insulin-dependent form of 
diabetes, while as many as 2,000 persons out of every 
100,000 are affected with the more common Type II form. 
The maintenance of normal blood sugar levels is achieved 
by the actions of several hormones, most notably insulin, but 
also glucagon, epinephrine, corticosteroids, and growth hor-
mone. Hypoglycemia, or low blood sugar, is characterized 
by below normal levels of blood glucose. On the other hand, 45 hyperglycemia is exemplified by higher than normal con-
centrations of glucose in the blood. A substance which 
functions to decrease blood glucose levels is said to exhibit 
There is good evidence that hyperglycemia conveys risks 
for all of the common late complications of diabetes melli-
tus, which are the major causes of excess morbidity and 
mortality in diabetics. However, there is no generally appli-
cable and consistently effective means of maintaining nor-a hypoglycemic effect. Such a substance is sometimes called 
a hypoglycemic agent. 50 ma! plasma glucose fluctuations in diabetics, and efforts to 
do so entail significant risks of causing frequent or severe 
hypoglycemic episodes. Nevertheless, common treatments 
include diet management and the use of insulin preparations 
The pancreas produces insulin which is released in 
response to increased blood glucose concentrations. Insulin 
works to lower the blood sugar level by stimulating the 
uptake of glucose by cells. Glucose is either used in cellular 
metabolism to produce energy, converted to glycogen for 55 
storage in the liver and muscles, or used in the production of 
triglycerides and fats. As opposed to insulin, glucagon, 
epinephrine and corticosteroids all operate to increase blood 
glucose concentrations. 
Many persons are afflicted with one of a genetically and 60 
clinically heterogeneous group of disorders that have glu-
cose intolerance (hyperglycemia) in common. A good syn-
opsis of these disorders is contained in The Merck Manual 
of Diagnosis and Therapy (Robert Berkow et al. eds., 16th 
ed., 1992). Impaired glucose tolerance, gestational diabetes 65 
and diabetes mellitus are diagnosed according to plasma 
glucose values in mg/di. The National Diabetes Data Group 
and oral hypoglycemic agents. 
Insulin preparations are classified as short, intermediate or 
long-acting. Preparations of purified porcine insulin, puri-
fied bovine insulin, semisynthetic human insulin, and bio-
synthetic human insulin are now available. Conventional 
insulin treatment includes one or two injections per day of 
intermediate-acting insulin, with or without smaller added 
doses of rapid-acting insulin in the same syringe. Compli-
cations of insulin treatment include severe hypoglycemia, 
local allergic reactions, generalized insulin allergy, immu-
nologic insulin resistance and local fat atrophy or hypertro-
phy. 
Oral hypoglycemic agents are not used to treat insulin-
dependent diabetes because they cannot prevent symptom-
5,531,991 
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atic hyperglycemia, but such agents can be effective when 
used in the treatment of non-insulin-dependent diabetes and 
other forms of glucose intolerance. Biguanides and sulfo-
4 
cell assays and are shown to lower blood glucose level in a 
feeding trial. The fractions, and particularly fraction I, 
exhibit a significant hypoglycemic effect. 
A better understanding of the invention, and the objects 
5 thereof, will be obtained from the following detailed 
description. 
ny lureas are the two historical classes of oral hypoglycemic 
agents. Biguanides, however, are not currently approved for 
treatment of diabetes in the United States. The sulfonylureas 
include tolbutarnide, chlorproparnide, acetohexamide, 
tolazamide, glyburide and glipizide and lower plasma glu-
cose by stimulating insulin secretion and also by enhancing 
insulin effect in some target tissues and inhibiting hepatic 1 o 
glucose synthesis. Authorities differ in the extent to which 
they recommend sulfonylureas. It is said that the sulfony-
lureas do not provide a rapid and consistently effective 
means of treating or preventing symptomatic hyperglycemia 
in patients with non-insulin-dependent diabetes, and in 15 
asymptomatic obese patients they are not consistently effec-
tive either in decreasing the hyperglycemia or in maintaining 
the commonly recommended target levels of plasma glu-
cose. Hypoglycemia is the most important complication of 
sulfonylurea treatment. Sufonylurea-induced hypoglycemia 20 
can be severe and may last or recur for days after treatment 
is stopped. It is recommended that sulfonylurea-treated 
patients who develop hypoglycemia should be hospitalized 
and closely monitored, even if they respond rapidly to initial 
treatment for hypoglycemia, as a mortality rate of 4.3% in 25 
patients hospitalized with sulfonylurea-induced hypoglyce-
mia has been reported. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
Chinese herbs have long been used in the treatment of an 
almost limitless list of maladies. Around the third century 
B.C., the book Nei Ching, popularly known as the Yellow 
Emperor's Classics of Internal Medicine, was authored by a 
group of Chinese physicians. Among other things, this book 
outlined the use of herbal treatments for a variety of bodily 
ailments. It is said to be the fundamental text of Chinese 
medicine. The first Chinese classic exclusively dealing with 
herbal medicine, the Classic of the Agriculture Emperor's 
Materia Medica, was published prior to the establishment of 
the East Han Dynasty (A.D. 25-220) and lists a total of 365 
herbs, including 252 plants, 67 animals, and 46 minerals said 
to be effective in treating 170 various diseases or afflictions. 
The classic An Outline of Matella Medica written by Shih-
Chen Li and published in 1578 contains approximately 
1,900,000 Chinese ideograms and a list of 1,892 herbs along 
with 11,096 herbal formulas. Modem day descriptions of 
herbs and their traditional usage can be found in Lu, Henry 
C., Legendary Chinese Healing Herbs (1991) and Reid, 
30 Daniel P., Chinese Herbal Medicine (1990). 
Considering the complications attendant to the use of 
insulin preparations and sulfonylureas in controlling blood 
glucose concentrations, there is a need for a new composi-
tion and method for treating hyperglycemia that is useful in 
the control of the high blood glucose levels associated with 
glucose intolerance, but that utilizes an organically derived 
composition which is easy to manufacture and relatively 
inexpensive. Preferably the new composition would be 35 
useful in treating non-insulin-dependent hyperglycemia and 
would provide an alternative to the use of sulfonylureas. 
In the first study conducted relating to the composition 
and method of the present invention, 24 Chinese herbs were 
assayed for their insulin potentiating activity. The Chinese 
herb of the present invention was selected for further study 
based upon the assay results. 
SUMMARY OF THE INVENTION 
The 24 herbs were separately stirred with a 20-fold excess 
(w/v) of 0.lN NH4OH for 2 hours and then centrifuged at 
l ,000xg for 20 minutes. Insulin potentiating activity of the 
40 supernatant of each Chinese herb extraction was evaluated 
using isolated adipocytes from rat epididymal fat tissue. 
It is therefore an object of this invention to overcome the 
limitations of the prior art by providing, as an adjunct to 
insulin therapy, a new composition and method for treating 
hyperglycemia, which composition and method do not uti-
lize insulin preparations or common sulfonylureas, but 45 
instead use a substance that is organically derived. 
Plastic containers were used exclusively for fat cell iso-
lation and assay. Two rats were sacrificed by decapitation 
and their epididymal fat pads removed. The distal portion of 
the fat pads was rinsed with 0.9% NaCl, minced with 
scissors, and incubated at 37° C. for 40 minutes in 6 ml of 
Krebs Ringer Phosphate (KRP) buffer containing 12 mg of 
collagenase in a water bath shaker at 200 rpm. The KRP 
contained 118 mM NaCl, 1.3 mM CaCl2 , 1.2 mM MgSO4 , 
It is another object of this invention to provide a compo-
sition and method for treating hyperglycemia that employ a 
substance having a high insulin potentiating activity. 
It is a further object of this invention to provide a 
composition and method for treating hyperglycemia using 
the most potent fraction of an extract of a naturally occurring 
plant. 
50 1 mM KH2PO4 , and 16.2 mM N~HPO4 -HCI (pH 7.4). The 
digested tissue was passed through a silk screen using a 
10-ml syringe. The preparation was then washed three times 
by centrifugation with KRP containing 2% albumin. Both 
KRP and KRP-albumin were millipore filtered and gassed 
55 with 0 2 . The material below the floating fat cells and any fat 
above the adipocytes were removed by aspiration. KRP-
albumin (10 ml) was added to disperse the washed fat cells. 
Fats cells remained viable for at least 4 hours. 
These and other objects are achieved by providing a 
composition and method for treating hyperglycemia which 
utilize an extract of a Chinese herb. The present invention 
uses an extract of the herb Polygonum multiflorum to obtain 
hypoglycemic effects. The herb is shown to have a high 
insulin potentiating activity. For use in the preferred embodi- 60 
ment of the present invention, the root of P. multiflorum is 
extracted with 0.1 N NH4 OH (20:1) (w/v) and centrifuged 
(1,000xg). The supernatant is applied to a Sephadex G-25 
column (50-150 u of particle size, 60x2.6 cm). Three 
fractions are collected and evaporated at room temperature 65 
to one-third to one-tenth of their original volume. The 
fractions exhibit a high insulin potentiating activity in fat 
Insulin and the indicated amount of sample to be tested 
were added to tubes that contained 1.9 ml of KRP-albumin, 
0.4 uCi(U-14C) glucose (313 Ci/mo!), and 67.5 ug of dex-
trose. Adipocytes (0.06 ml) were added, and caps containing 
center wells were used to seal the tubes. After incubation for 
2 hours at 37° C. and shaking at 150 rpm, 0.2 ml ofhyamine 
hydroxide was added to the center well, and 0.3 ml of 2N 
H2SO4 was injected into the incubation mixture to stop the 
reaction. The tubes were incubated for 30 minutes to allow 
5,531,991 
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the hyamine hydroxide to trap 14CO2 • The center wells were 
removed, carefully wiped, and added to 10 ml of Aquasol II 
and counted in a beta counter. 
6 
effect of P. multijlorum supplementation in pigeons fed a 
hypercholesterolemic diet. 
As shown in Table 2 below, the insulin potentiating 
activity of Chinese herb No. 13 (P. multijlorum) was higher 5 
than all other Chinese herbs tested. It was thus recognized 
that P. multijlo rum, due to its high insulin potentiating 
activity in vitro, might enhance glucose utilization. 
Another study of the effects of P. multijlorum on choles-
terol and related enzymes in rats was conducted by Niou, et 
al. in 1988. Niou, J., et al., The Protective Effect Of 
Baishouwu on the Liver of Hyperlipidemic Rats, ACTA 
Medicine Sinica, 3:26-27 (1988). In this study, groups fed 
a hypercholesterolemic diet including either powdered P. 
multijlorum or an extract from P. multijlorum showed sig-
TABLE 2 
INSULIN POTENTIATION OF CHINESE HERBS 
SAMPLES 
Standard Yeast #1 
Standard Yeast #2 
No. 1 
No. 2 
No. 3 
No. 4 
No. 5 
No. 6 
No. 7 
No. 8 
No. 9 
No. 10 
No. 11 
No. 12 
Polygonum multif/orum 
No. 14 
No. 15 
No. 16 
No. 17 
No. 18 
No. 19 
No. 20 
No. 21 
No. 22 
No. 23 
No. 24 
INSULIN POTENTIATION 
2.9 
1.7 
0.9 
1.1 
0.6 
0.5 
1.5 
1.1 
1.0 
1.1 
1.3 
0.8 
1.2 
2.1 
4.1 
0.9 
1.2 
1.3 
1.2 
1.2 
1.2 
1.2 
1.3 
1.0 
1.1 
1.1 
The contemporary Chinese medicinal usage of the herb 
Polygonum multijlorum, also known as He Shou Wu and 
more commonly as "knotgrass," is said to show effective-
ness against high blood pressure and hardening of the veins 
and arteries. There have been several studies of P. multijlo-
rum in animals, but very little is known of its physiological 
and chemical properties, especially as related to glucose 
metabolism. 
PRIOR ART 
The relationship between cholesterol and P. multijlorum 
was investigated by Guo and Song in 1986. Guo, G. and 
Song, Z., Effect of Shouwuyanshoudan and Nicotinic Acid 
on Serum Cholesterol in Pigeons Fed Hypercholesterolemic 
Diets, J. Tianjing Medicine and Pharmacology 8: 40-42 
(1986). In their study, eighty pigeons were fed a hypercho-
lesterolemic diet and were divided into three groups: a P. 
multijlorum supplemented (2 g/day) group (n=20), a nico-
tinic acid supplemented (100 mg/day) group (n=20), and a 
control group (n=40). After two months, all pigeons, except 
24 in the control group, were sacrificed. The 24 pigeons 
were divided into two groups again as a P. multijlorum 
supplemented group and a control group. The results of this 
study showed that mean serum cholesterol levels for both 
the P. multijlorum supplemented and nicotinic acid supple-
ment groups were significantly decreased as compared to the 
control group. In the continued study of the 24 pigeons, 
serum cholesterol was also significantly decreased in the P. 
multijlorum supplemented group as compared to the control 
group. In sum, the study showed the hypocholesterolemic 
10 nificantly decreased serum cholesterol levels as compared to 
the group fed the hypercholesterolemic diet alone. Addition-
ally, there were many neutral fat drops in the lobules of the 
liver in the group fed the hypercholesterolemic diet. Both P. 
multifiorum supplemented groups had very few fat drops and 
compared favorably to a normal diet group. The results 
15 
suggested that P. multijlorum could be considered as a 
hypolipidemic agent. 
More lipidemic indices and atherosclerotic changes tied to 
the use of P. multijlorum have been investigated in the 
Japanese quail by Wang and Jin. Wang, W. and Jin, D., 
20 Ethanol Extract of Zhishouwu in Preventing Atherosclerosis 
of Japanese Quail, Journal of Chinese Medicine Combined 
with Western Medicine 4: 748-750 (1984). In this trial, 46 
Japanese quail were divided into four groups. These groups 
were fed hypercholesterolemic diets supplemented with 
25 water (control) or with small, medium or large doses of a P. 
multijlorum extract. The results showed that plasma HDL-
cholesterol levels of the three P. multijlorum supplemented 
groups were increased as compared to the control group. 
Likewise, the HDL cholesterol/total cholesterol ratios in the 
30 three P. multijlorum supplemented groups were increased 
after 2-5 weeks. Moreover, plasma cholesterol and choles-
terol esters in the three P. multijlorum supplemented groups 
were decreased compared to the control group after six 
weeks. Plasma triglyceride levels were also decreased as 
35 compared to the control group. Further, atherosclerotic 
changes in the aorta with the three levels of P. multijlorum 
supplementation were less than in the control group, espe-
cially in the large dose supplementation group. 
In another study, stimulation of the conversion of choles-
40 tern! to cholic acid in vitro utilizing three concentrations of 
P. multijlorum was observed by Xu and Li in 1987. The 
investigation showed that the lowest concentration was the 
best for stimulating conversion of cholesterol to cholic acid. 
Xu, C. and Li, Y., The Effect of Heshouwu on Hepatic Cell 
45 Induced by (3H)-cholesterol in Vitro, ACTA Chinese Medi-
cine and Pharmacology 3:39-40 (1987). 
The use of P. multijlorum in various products also has 
been disclosed in several unrelated patents. U.S. Pat. No. 
4,797,421 divulges the use of P. multijlorum in a proantho-
50 cyanidin antioxidant compound. (Col. 9, 1.23-50). Extracts 
of knotgrass are disclosed as an ingredient in a deodorant in 
U.S. Pat. No. 4,883,651. Herbal smoking materials incor-
porating extracts of P. multijlorum were revealed in U.S. Pat. 
No. 5,135,010. (Col. 1, 1.52-61). Further, P. multijlorum 
55 was disclosed as a potential ingredient in a plant component 
said to be effective in the control of protozoa! disease in U.S. 
Pat. No. 5,135,746. (Col. 4, 1.25-38). Still further, 
Polygonum bistoria L. was declared to be effective in the 
treatment of HIV related disease in vitro in U.S. Pat. No. 
60 5,178,865. (Table 1, #30). Lastly, an extraction procedure 
for P. multijlorum resulting in an extract that is an isolation 
of two stilbene glycoside gallates together with galloyl 
procyandins is disclosed in Nonaka, G., et al., Stilbene 
Glycoside Galla/es and Proanthocyanidins from Polygonum 
65 multijlorum, Phytochemistry, 21:429-432 (1982). 
It can thus be appreciated that, until now, the physiologi-
cal and chemical properties of P. multijlorum as related to 
5,531,991 
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glucose metabolism have gone almost entirely undiscov-
ered. 
FRACTIONATION AND EXPERIMENTATION 5 
After isolating P. multiflorum as the Chinese herb exhib-
iting the highest insulin potentiating activity, a study was 
conducted concerning the effects of fractions from P. mul-
tiflorum on plasma glucose and cholesterol in mice fed a 
hypercholesterolemic diet. The purpose of this study was to 10 
test the effects of different fractions of P. multiflorum sepa~ 
rated on a Sephadex G-25 column on glucose and choles-
terol in mice fed hypercholesterolemic diets. 
A sample of P. multiflorum was ground to a fine powder. 
(It is preferred that the root of P. multiflorum be utilized.) 15 
The powder was stirred at a medium speed with an excess 
20: 1 (w/v) ofO. IN NH4OH for 2 hours and then centrifuged 
at l,000xg for 20 minutes. (The supernatant may be refrig-
erated until chromatographed.) The supernatant (10 ml) was 
applied to a medium grade Sephadex G-25 column (50-150 20 
u of particle size, 60x2.6 cm) and was eluted with distilled 
deionized water. Three fractions were collected. The first 
fraction was manifested in a dark brown band, the second in 
TABLE 3-continued 
PLASMA GLUCOSE, INSULIN, AND CHOLESTEROL IN 
MICE SUPPLEMENTED WITH FRACTION 1, 2, OR 3 OF 
EXTRACT (EXPERIMENT 1)1 
F3 vs Ct 0.07 0.07 0.67 
1Values are means± SEM; n = 9-10. 
2Significant difference from control group. 
The mean plasma glucose in mice supplemented with 
combinations of fraction 1 and 2 (195 mg/di) or fraction 1 
and 3 (188 mg/di) was significantly decreased (P<0.04 and 
P<0.02, respectively) compared to the control group (See 
table 4). 
Group 
TABLE4 
MEAN PLASMA GLUCOSE, INSULIN, AND 
CHOLESTEROL IN MICE SUPPLEMENTED 
WITH COMBINATIONS OF FRACTIONS 
FROM EXTRACT (EXPERIMENT 2)1•2 
Glucose 
(mg/dl) 
Insulin 
(uU/ml) 
Cholesterol 
(mg/dl) 
a light brown band, and the third in a pinkish brown band. 
The three fractions were evaporated at room temperature to 
1/J of their original volume for Experiment 1 and to 1/10 of 
their original volume for Experiment 2. Each combination of 
fractions was prepared by mixing the appropriate fractions 
and equal concentrations were maintained. The plasma 
glucose and cholesterol were analyzed using enzymatic 
methods. Insulin was analyzed by radioimmunoassay. 
Fl & 2 
25 Fl & 3 
F2 & 3 
194.6 ± 10.8" 
188.3 ± 11.4b 
197.6 ± 10.8 
211.8 ± 10.8 
214.7 ± 10.3 
225.2 ± 10.3 
13.9 ± 2.6d 
11.2 ± 2.7d 
15.1 ± 2.6d 
21.8 ± 2.6d 
24.9 ± 2.4 
31.4 ± 2.4 
209.7 ± 13.2 
225.1 ± 14.0 
240.0 ± 13.2c 
197.4 ± 13.2 
196.4 ± 12.6 
193.6 ± 12.6 
Fl & 2 & 3 
Extract 
Control 
30 'Values are means± SEM; n = 10-11. 
2The significant differences from control (a: P < 0.05; b: P < 0.02; c: P < 0.01; 
d: P < 0.001. 
In Experiment No. 1, thirty-nine male weanling mice 
were randomly assigned to four groups: Fraction 1, 2, 3, or 
the control. In experiment No. 2, sixty-one male weanling 35 
mice were randomly assigned to six groups: fraction 1 and 
2; fraction 1 and 3; fraction 2 and 3; fraction 1 and 2 and 3; 
crude extract; or control. All mice were fed a hypercholes-
terolemic diet with 1.0% cholesterol and 0.5% cholic acid. 
Each mouse was given 100 microliters of fraction(s) or 40 
water orally by micropipette daily. Experiments 1 and 2 
were terminated after 10 and 9 weeks, respectively. 
The mean plasma insulin concentrations in groups supple-
mented with combinations of fraction 1 and 2, fraction 1 and 
3, fraction 2 and 3, and fraction I and 2 and 3 were all 
significantly lower than the control group (Table 4). 
No fraction alone, nor the combinations of fractions, 
decreased plasma cholesterol. In fact, the mean plasma 
cholesterol concentration in mice fed fraction 2 and 3 (240 
mg/di) was significantly (P<0.01) higher than the control 
group (194 mg/di) (Table 4). 
A significant hypoglycemic effect was found when frac-
tion I was supplemented alone. The combination of fraction 
I and 2 or fraction 1 and 3 also lowered plasma glucose 
The results showed that mean plasma glucose was 
decreased significantly by fractions 1; 1 and 2; and 1 and 3. 
Mean plasma insulin was significantly decreased by frac-
tions 1 and 2; 1 and 3; 2 and 3; and fraction 1 and 2 and 3. 
No fraction(s) had hypocholesterolemic effects. 
45 significantly. This might be explained by insulin potentia-
tion. This effect was demonstrated by fraction 1, fraction 1 
and 2, fraction I and 3. Each fraction, and the combinations 
of fractions, investigated caused a hypoglycemic effect 
instead of the hypocholesterolemic effect observed in pre-
The mean plasma glucose in the fraction 1 supplemented 
group (245 mg/dl) was significantly decreased compared 
with the control group (294 mg/di) (P<0.04) (See Table 3). 50 
TABLE 3 
PLASMA GLUCOSE, INSULIN, AND CHOLESTEROL IN 
MICE SUPPLEMENTED WITH FRACTION 1, 2, OR 3 OF 
EXTRACT (EXPERIMENT 1)1 
Glucose Insulin Cholesterol 
Group (mg/dl) (uU/ml) (mg/dl) 
Fract 1 244.8 ± 16.2 8.5 ± 5.0 243.6 ± 15.2 
Fract 2 257.0 ± 18.0 14.9 ± 5.5 261.7 ± 16.0 
Fract 3 249.4 ± 16.2 30.4 ± 4.9 238.1 ± 15.2 
Control 293.9 ± 17.0 16.5 ± 5.5 247.5 ± 16.0 
Source of 
variation Analysis of Variance P Value 
Fl vs Ct 0.042 0.29 0.86 
F2 vs Ct 0.15 0.83 0.53 
vious studies. 
In another study, the effects of fraction 1 on plasma 
glucose and cholesterol in obese mice fed a hypercholester-
olemic diet was tested. The purpose of the study was to 
investigate a possible hypoglycemic effect connected with 
55 fraction 1 of P. multiflorum in older, obese mice. 
60 
65 
For this study, fraction I was collected in the same fashion 
as the prior study and was evaporated to 1/3 of its original 
volume at room temperature. Nineteen obese male mice 
were randomly assigned to two groups: Fraction 1 or con-
trol. The mice were fed a casein-based hypercholesterolemic 
diet containing 1 % cholesterol and 0.5% cholic acid. Each 
mouse was given 100 microliters of fraction 1 or water 
orally by micropipette daily. After seven weeks, the mice 
were fasted 14 hours and were then given an oral glucose 
load (1 mg glucose/g body weight as a 50% solution) 60 
minutes before sacrifice. The mice were anesthetized and 
exsanguinated by heart puncture. Again, plasma glucose and 
5,531,991 
9 
cholesterol were analyzed using enzymatic methods, and 
insulin was analyzed by radioimmunoassay. 
In this study, mean plasma glucose and insulin ratios were 
not affected by fraction 1 (See Table 5). 
10 
2. In a host with an unduly elevated blood glucose 
concentration, a method for treating hyperglycemia, which 
comprises the administration of an a blood glucose lowering 
effective amount of a composition derived from an extract of 
TABLE 5 
MEAN VALUE OF GLUCOSE, lNSULlN, AND 
CHOLESTEROL IN OBESE MICE SUPPLEMENTED 
WITH FRACTION 1 OF EXTRACT' 
5 Polygonum multiflorum, said Polygonum multiflorum hav-
ing been ground, then stirred with 0.lN NH40H to obtain 
said extract, said extract having been centrifuged to obtain 
a supernatant, said supernatant having been eluted in a 
medium grade separator column of Sephadex G-25 to obtain 
10 
said composition, said composition being selected from the 
group consisting of: 
GLUCOSE INSULJN 
GROUP (MG/DL) (uU/ml) 
FRACTION 393.6 ± 72.3 63.7 ± 22.3 
CONTROL 417.3±36.1 79.3 ± 25.6 
PVALUE 0.4 0.2 
1Values are means± SEM; n = 9-10. 
2Significant difference from control group. 
CHOLESTEROL 
(mg/dl) 
168.7 ± 39.0 
237.1 ± 46.9 
0.0032 15 
However, the mean plasma cholesterol in the group 
supplemented with fraction 1 (169±39 mg/dl) was signifi- 20 
cantly lower (P<0.003) than the control group (237±47 
mg/dl) (Table 5). Here, fraction 1 played the same role as 
had been previously observed with crude extracts of P. 
multiflorum in pigeons, rats and Japanese quail. 
(a) a first fraction eluted from said separator column, said 
first fraction being manifest in a dark brown band; 
(b) a combination of said first fraction and a second 
fraction eluted from said separator column, said second 
fraction being manifest in a light brown band; 
(c) a combination of said first fraction and a third fraction 
eluted from said separator column, said third fraction 
being manifest in a pinkish brown band; 
(d) a combination of said second fraction and said third 
fraction; and 
( e) a combination of said first fraction, said second 
fraction and said third fraction. Fraction 1 did not have a hypoglycemic effect in the older 25 
obese mice as it did in the weanling lean mice .. However, 
there were many differences, such as animal model traits, 
weight, age, diets, length of the experiment, and blood 
sampling times that might have contributed to this result. 
3. The method according to claim 2 wherein said first 
fraction, said second fraction and said third fraction of said 
group are evaporated to one-third of their original volumes. 
4. The method according to claim 2 wherein said first 
30 fraction, said second fraction and said third fraction of said group are evaporated to one-tenth of their original volumes. 
5. A composition for treating hyperglycemia derived from 
an extract of Polygonum multiflorum, said Polygonum mul-
tiflorum having been ground, then stirred with 0.lN NH4OH 
The claims and the specification describe the invention 
presented, and the terms that are employed in the claims 
draw their meaning from the use of such terms in the 
specification. The same terms employed in the prior art may 
be broader in meaning than specifically employed herein. 
Whenever there is a question between the broader definition 
of such terms used in the prior art and the more specific use 
of the terms herein, the more specific meaning is meant. 
While the invention has been described with a certain 
degree of particularity, it is manifest that many changes may 
be made in the details of construction and the arrangement 
35 to obtain said extract, said extract having been centrifuged 
to obtain a supernatant, said supernatant having been eluted 
in a medium grade separator column of Sephadex G-25 to 
obtain said composition, said composition being selected 
from the group consisting of: 
of components without departing from the spirit and scope 40 
of this disclosure. It is understood that the invention is not 
limited to the embodiment set forth herein for purposes of 
exemplification, but is to be limited on] y by the scope of the 
attached claim or claims, including the full range of equiva-
lency to which each element thereof is entitled. 45 
What is claimed is: 
1. In a host with an unduly elevated blood glucose 
concentration, a method for treating hyperglycemia, which 
comprises: 
a. grinding a sample of Polygonum multiflorum to obtain 50 
a fine powder; 
b. stirring said powder with 0.lN NH4OH to obtain an 
extract; 
c. centrifuging said extract to obtain a supernatant; 
d. applying the supernatant to a medium grade separator 55 
column of Sephadex G-25 to obtain a first fraction 
having a dark brown color; and 
e. ingesting a blood glucose lowering effective amount of 
said first fraction. 
(a) a first fraction eluted from said separator column, said 
first fraction being manifest in a dark brown band; 
(b) a combination of said first fraction and a second 
fraction eluted from said separator column, said second 
fraction being manifest in a light brown band; 
(c) a combination of said first fraction and a third fraction 
eluted from said separator column, said third fraction 
being manifest in a pinkish brown band; 
(d) a combination of said second fraction and said third 
fraction; and 
(e) a combination of said first fraction, said second 
fraction and· said third fraction. 
6. The composition according to claim 5 wherein said first 
fraction, said second fraction and said third fraction of said 
group are evaporated to one-third of their original volumes. 
7. The composition according to claim 5 wherein said first 
fraction, said second fraction and said third fraction of said 
group are evaporated to one-tenth of their original volumes. 
* * * * * 
